ITRM(Delisted)
Iterum Therapeutics (ITRM) Stock Statistics, Valuation & Financial Metrics
Total Valuation
Iterum Therapeutics market cap is -- and enterprise value is --.
Share Statistics
Iterum Therapeutics has 53.29M shares outstanding, with a free float of 52.42M.
Valuation Ratios
Iterum Therapeutics's PE ratio is --, PB ratio is --, and PS ratio is --, showing whether the stock looks expensive or cheap.
Solvency
Iterum Therapeutics debt-to-equity ratio is -2.91 and debt-to-assets ratio is 1.23.
Liquidity
Iterum Therapeutics's current ratio is 2.13, quick ratio is 1.96, and cash ratio is 1.71, showing its short-term liquidity position.
Return on Capital
Iterum Therapeutics's ROE is --, ROA is -111.35%, and ROIC is -167.03%, showing its return on capital profile.
Profitability
Iterum Therapeutics gross margin is --, operating margin is --, and net margin is --.
Operating Efficiency
Iterum Therapeutics's asset turnover is --, inventory turnover is 0.48, and receivables turnover is --, indicating its operating efficiency.
Income Statement
Iterum Therapeutics's revenue is --, gross profit is 116.00K, net income is -24.08M, and EBITDA is -15.84M.
Balance Sheet
Iterum Therapeutics's total debt is 21.50M, net debt is 10.49M, total equity is -7.38M, and cash is 11.00M.
Cash Flow Statement
Iterum Therapeutics's operating cash flow is -19.51M, free cash flow is -19.53M, and CapEx is -14.00K.
Dividends & Yields
Iterum Therapeutics dividend yield is --, with a payout ratio of -- and dividend per share of --.
Analyst Rating
Iterum Therapeutics's latest analyst rating is Unrate, with an analyst target price of --.
Company Info
A clinical-stage pharmaceutical company focused on therapeutics for multi-drug rsistant pathogens
Per Share Metrics
Iterum Therapeutics's EPS is -0.72, book value per share is -0.15, and free cash flow per share is -0.17.
